Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ANTHONY PAUL CONLEY and NEETA SOMAIAH.
ANTHONY PAUL CONLEY
Connection Strength
3.518
NEETA SOMAIAH
  1. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort. Rare Tumors. 2024; 16:20363613241271669.
    View in: PubMed
    Score: 0.245
  2. Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors. Cancers (Basel). 2024 Apr 27; 16(9).
    View in: PubMed
    Score: 0.240
  3. Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter? Cancers (Basel). 2024 Feb 23; 16(5).
    View in: PubMed
    Score: 0.237
  4. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Apr; 5(4):625-641.
    View in: PubMed
    Score: 0.237
  5. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med. 2023 02; 12(4):4282-4293.
    View in: PubMed
    Score: 0.215
  6. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022 09; 23(9):1156-1166.
    View in: PubMed
    Score: 0.213
  7. Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma. J Immunother. 2022 10 01; 45(8):374-378.
    View in: PubMed
    Score: 0.213
  8. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma. 2020; 2020:8363986.
    View in: PubMed
    Score: 0.183
  9. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel). 2019 May 15; 11(5).
    View in: PubMed
    Score: 0.170
  10. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018 Apr 13; 9(28):19891-19899.
    View in: PubMed
    Score: 0.158
  11. Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion. Sarcoma. 2017; 2017:7495914.
    View in: PubMed
    Score: 0.152
  12. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Sci Rep. 2017 08 25; 7(1):9519.
    View in: PubMed
    Score: 0.151
  13. Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. J Glob Oncol. 2018 09; 4:1-6.
    View in: PubMed
    Score: 0.150
  14. Does the Primary Tumor Site Drive Biology for Patients With Synovial Sarcoma? Am J Clin Oncol. 2024 Sep 03.
    View in: PubMed
    Score: 0.062
  15. Safety and Efficacy of Percutaneous Cryoablation for Recurrent or Metastatic Soft-Tissue Sarcoma in Adult Patients. AJR Am J Roentgenol. 2024 Oct; 223(4):e2431490.
    View in: PubMed
    Score: 0.061
  16. High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers (Basel). 2024 May 01; 16(9).
    View in: PubMed
    Score: 0.060
  17. Safety and efficacy of percutaneous image-guided ablation for soft tissue sarcoma metastases to the liver. Cancer. 2024 Aug 01; 130(15):2703-2712.
    View in: PubMed
    Score: 0.060
  18. SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection. Int J Radiat Oncol Biol Phys. 2024 Mar 15; 118(4):971-978.
    View in: PubMed
    Score: 0.058
  19. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.
    View in: PubMed
    Score: 0.056
  20. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer. 2023 07 15; 129(14):2201-2213.
    View in: PubMed
    Score: 0.056
  21. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. 2023 01 17; 29(2):401-409.
    View in: PubMed
    Score: 0.055
  22. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol. 2022; 12:1008484.
    View in: PubMed
    Score: 0.054
  23. Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. Cancer. 2022 09 15; 128(18):3383-3391.
    View in: PubMed
    Score: 0.053
  24. Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions. Adv Radiat Oncol. 2022 May-Jun; 7(3):100913.
    View in: PubMed
    Score: 0.051
  25. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat. 2021 Apr; 186(3):871-882.
    View in: PubMed
    Score: 0.048
  26. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Mol Cancer Ther. 2020 05; 19(5):1165-1172.
    View in: PubMed
    Score: 0.045
  27. Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020 02 21; 11(1):1008.
    View in: PubMed
    Score: 0.045
  28. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017 12 19; 5(1):100.
    View in: PubMed
    Score: 0.039
  29. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Sci Rep. 2017 09 19; 7(1):11836.
    View in: PubMed
    Score: 0.038
  30. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist. 2017 10; 22(10):1271-1277.
    View in: PubMed
    Score: 0.038
  31. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017 Jun 13; 8(24):39254-39267.
    View in: PubMed
    Score: 0.037
  32. Progressive and Reversible Conduction Disease With Checkpoint Inhibitors. Can J Cardiol. 2017 10; 33(10):1335.e13-1335.e15.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.